Rise of the armoured CARs (and the drive toward solid tumour) Cell therapy researchers love their ... presented new data on how it’s using CAR-macrophages to navigate the TME in patients with ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An ...

Furthermore, adoptive macrophage and natural killer cell therapies hold promise for not only their ... including chimeric antigen receptor (CAR)-T-cell therapy, tumor-infiltrating lymphocyte (TIL) ...

The $4.9 billion acquisition of Forty Seven by Gilead is an example of the explosive excitement and investment into macrophage-directed therapies, utilizing CD47 checkpoint blockades ...

While the use of chimeric antigen receptor (CAR) T-cell therapy has increased rapidly ... Lenzilumab, a ...

Chimeric antigen receptor (CAR) T cell therapy has changed the treatment landscape for certain blood cancers. Standardizing CAR T cell manufacturing is one of the key considerations for improving ...

It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 ...

BrainChild Bio Inc. announced plans to advance a novel CAR T-cell therapy to treat young people with a rare, incurable pediatric brain tumor. Image: Adobe Stock DIPG, a tumor that arises in the ...